COVID-19 and breast cancer: How should we treat our patients?

Updated results from KEYNOTE-426 for metastatic kidney cancer

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

PARP inhibitors in prostate cancer: Choices of tests and how to test?

ASCO 2020: Breast cancer roundup

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

ASCO 2020: Updates in renal cancer

Highlights from ASCO 2020

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway